Haploidentical hematopoietic cell transplantation (Haplo-HCT) using ex vivo TCR-αβ–Depleted grafts and upfront memory T-cell add-back mitigates the negative impact of pre-transplant measurable residual disease (MRD) in adults with Acute Myeloid Leukemia (AML) and acute lymphoblastic leukemia (ALL) compared to matched related and unrelated donor transplantation